Skip NavigationSkip to Content

Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease

  1. Author:
    Robinson, Emma
    Rodriguez, Isabel
    Argueta, Victor
    Xie, Yi
    Lou, Hong
    Milano, Rose
    Lee, Hyo Jung
    Burdett, Laurie
    Mishra,Sambit
    Yeager,Meredith
    Mirabello, Lisa
    Dean, Michael
    Orozco, Roberto
  2. Author Address

    HLA Immunogenetics, Basic Science Program, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA., Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA., Hospital General San Juan de Dios, Guatemala City, Guatemala., Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.,
    1. Year: 2024
    2. Date: Dec 11
    3. Epub Date: 2024 12 11
  1. Journal: Tumour Virus Research
    1. Pages: 200299
  2. Type of Article: Article
  3. Article Number: 200299
  1. Abstract:

    To better understand cervical cancer progression, we analyzed RNA from 262 biopsies from women referred for colposcopy. We determined the HPV type and analyzed the expression of 51 genes. HPV31 was significantly more prevalent in precancer than stage 1 cancer and invasive cancer (p < 0.0001), and HPV16 increased in invasive disease (p < 0.0001). CCNE1, MELTF, and ULBP2 were significantly increased in HPV16-positive compared to HPV31 precancers, while NECTIN2 and HLA-E expression decreased. Markers of the innate immune system, DNA repair genes, and cell cycle genes are significantly increased during cancer progression (p = 0.0001). In contrast, the TP53 and RB1 tumor suppressor gene expression is significantly decreased in cancer cells. The T cell markers CD28 and FLT3LG expression decreased in cancer while FOXP3, IDO1, and ULBP2 expression increased. There is a significantly higher survival rate in individuals with increased expression of CD28 (p = 0.0005), FOXP3 (p = 0.0002), IDO1 (p = 0.038), FLT3LG (p = 0.026), APOBEC3B (p = 0.0011), and RUNX3 (p = 0.019), and a significantly lower survival rate in individuals with increased expression of ULBP2 (p = 0.035). These results will help us elucidate the molecular factors influencing the progression of cervical precancer to cancer. Understanding the risk of progression of specific HPV types and sublineages may aid in the triage of positive patients, and better knowledge of the immune response may aid in developing and applying immunotherapies. Copyright © 2024. Published by Elsevier B.V.

    See More

External Sources

  1. DOI: 10.1016/j.tvr.2024.200299
  2. PMID: 39672307
  3. PII : S2666-6790(24)00023-5

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel